Details of the Drug Combinations

General Information of This Drug (ID: DM8Y4JS)

Drug Name
Quizartinib   DM8Y4JS
Synonyms AC220
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
leukaemia 2A60-2B33 Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
AC220 + Idarubicin DCTIM2Z Idarubicin Acute Myeloid Leukemia [3]
AC220 + Etoposide DCGLUFR Etoposide Lymphoblastic Leukemia, Acute, Childhood [4]
AC220 + Azacitidine DC080LO Azacitidine FLT3 Gene Mutation Negative [5]
Methotrexate + AC220 DC123FL Methotrexate Lymphoblastic Leukemia, Acute, Childhood [4]
Venetoclax + AC220 DC4UD35 Venetoclax Leukemia, Myeloid, Acute [6]
Venetoclax + AC220 DCNERRM Venetoclax Leukemia, Myeloid, Acute [6]
Venetoclax + AC220 DCSKJGQ Venetoclax Acute Myeloid Leukemia With FLT3/ITD Mutation [7]
AC220 + Idarubicin DCD0UHD Idarubicin Acute Myeloid Leukemia [8]
AC220 + Cytarabine DCEA0IL Cytarabine Acute Myeloid Leukemia [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216993
2 ClinicalTrials.gov (NCT02039726) An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02834390) Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
4 ClinicalTrials.gov (NCT01411267) AC220 for Children With Relapsed/Refractory ALL or AML
5 ClinicalTrials.gov (NCT01892371) Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
6 ClinicalTrials.gov (NCT04687761) Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
7 ClinicalTrials.gov (NCT03735875) Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
8 ClinicalTrials.gov (NCT04107727) Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
9 ClinicalTrials.gov (NCT02668653) Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)